NASDAQ:FBIO

Fortress Biotech Q2 2025 Earnings Results & Report

Fortress Biotech logo
$1.82 +0.11 (+6.43%)
Closing price 04:00 PM Eastern
Extended Trading
$1.82 0.00 (-0.11%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Fortress Biotech missed analyst earnings expectations but beat on revenue in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$0.46 versus the -$0.31 consensus estimate, while revenue of $16.41 million topped the $14.53 million estimate by $1.88 million.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call Date
Conference Call
4:00 PM ET

Fortress Biotech EPS Results

Actual EPS
-$0.46
Consensus EPS
-$0.31
Beat/Miss
Missed by -$0.15
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Fortress Biotech Revenue Results

Actual Revenue
$16.41 million
Expected Revenue
$14.53 million
Beat/Miss
Beat by +$1.88 million
YoY Revenue Growth
N/A

Fortress Biotech Q2 2025 Earnings FAQ

Fortress Biotech (NASDAQ:FBIO) reported earnings of -$0.46 per share for Q2 2025, missing the consensus estimate of -$0.31. The report was announced on Thursday, August 14, 2025.

Fortress Biotech reported revenue of $16.41 million for Q2 2025, against a consensus estimate of $14.53 million.

Fortress Biotech Earnings Headlines

The Democrats can’t stop this
Porter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypassing Congress under a national emergency. His new briefing outlines three steps to prepare and names a core group of assets tied to the initiative that he says could surge. He points to the 1970s Nixon-era reset, which reportedly minted an average of 1,300 new millionaires a day for over half a century.tc pixel
Fortress Biotech (FBIO) Projected to Post Earnings on Monday
See More Fortress Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fortress Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fortress Biotech and other key companies, straight to your email.

About Fortress Biotech

Fortress Biotech (NASDAQ:FBIO) is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs.

The company’s activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development. Products are commercialized primarily in the United States, directly or through affiliated companies.

Founded in 2006, Fortress Biotech has also established and supported subsidiary and affiliate companies to develop and commercialize therapeutic programs. The company is led by founder Lindsay A. Rosenwald, M.D., who serves as its chairman, president and chief executive officer.

View Fortress Biotech Profile